moneyheap
INCY · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Incyte Corporation (INCY) stock moving?
Incyte's news flow over the last two weeks is mostly positive but mixed on valuation. The Nov 10 Natera clinical collaboration adds a Phase II colorectal cancer study for INCA33890, a pipeline asset that is still early and not yet a revenue driver. The Nov 4 disclosure of a one-time $246M CMS settlement benefit included in Opzelura net sales guidance is the most financially material item, though it is non-recurring. The Oct 29 Q3 results were filed via 8-K, but the press release text provided does not include the figures, so the quarter's underlying numbers cannot be assessed here. Analysts reacted after the quarter: Oppenheimer upgraded to Outperform ($144), Barclays raised to $143, RBC to $117 and Evercore to $127, while Wells Fargo cut to $127 and Leerink trimmed to $150 and Bernstein raised to $108 with Market Perform. The average of the seven targets cited is about $131, roughly 9% above the $120.30 close on Nov 10. Price action confirms a constructive but unhurried tone. The stock jumped 3.1% on Oct 30 on 2.84M shares after the results and analyst updates, touched an intraday high of $123.33 on Nov 4, and has since traded in a $118 to $122 band. Volume on Nov 10 was 1.80M shares, below the recent average of roughly 2.0M, so the collaboration news did not produce a volume spike. Key risks include a wide spread of analyst targets, the one-time nature of the CMS benefit, and dependence on early-stage pipeline progress.
News behind the analysis
- Natera and Incyte Announce Clinical Collaboration for Phase II Colorectal Cancer StudyNatera and Incyte signed a clinical collaboration to evaluate Incyte's investigational bispecific immunotherapy INCA33890 in a new Phase II study for stage 2/3 colorectal cancer patients.
- Natera Enters Into Clinical Collaboration Agreement With Incyte For New Phase II Study In Colorectal CancerBenzinga reports the same Natera collaboration for a Phase II colorectal cancer study of Incyte's INCA33890.
- Leerink Partners Maintains Outperform on Incyte, Lowers Price Target to $150Leerink keeps its Outperform rating but trims its price target to $150 from $154.
- Incyte Discloses $246 Million Benefit from CMS Litigation SettlementIncyte's net sales guidance for Opzelura includes a one-time $246 million benefit from a settlement with the Centers for Medicare and Medicaid Services.
- Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026Incyte will present new hematology clinical data at the 68th American Society of Hematology Annual Meeting and Exposition.
- Incyte's Ruxolitinib Phosphate Cream Approved in Singapore for VitiligoPartner Rxilient Medical received Singapore approval for ruxolitinib phosphate cream (Lumirix) for non-segmental vitiligo.
- Bernstein Adjusts Incyte Price Target to $108Bernstein keeps a Market Perform rating and raises its price target to $108 from $104.
- Oppenheimer Upgrades Incyte to OutperformOppenheimer upgrades Incyte from Market Perform to Outperform with a new $144 price target.
- Barclays Maintains Overweight on Incyte, Raises Price Target to $143Barclays keeps its Overweight rating and raises its price target to $143.
About Incyte Genomics Inc
Incyte is a biopharmaceutical company based in Wilmington, Delaware, that develops and sells medicines for blood cancers, other cancers, and inflammatory and autoimmune skin conditions. It is best known for Jakafi (ruxolitinib), a JAK-inhibitor pill for bone marrow cancers and graft-versus-host disease, and is trying to build products that can keep it growing after Jakafi's US patent protection ends, which is expected around 2028–2029.
How it makes money
Most of its money comes from product sales: about $5.1–5.3 billion in net sales expected for 2026. Jakafi is still the biggest product, at roughly 55–60% of sales. Opzelura, a ruxolitinib cream for eczema (atopic dermatitis) and vitiligo, is expected to bring in about $1.05–1.1 billion. A growing group of blood-cancer and cancer drugs (Niktimvo, Monjuvi, Zynyz and others) makes up most of the rest, at about $0.9 billion. Incyte also earns royalties and milestone payments from partners. The largest is royalties from Novartis on sales of Jakavi (Jakafi's name outside the US) and from Eli Lilly on Olumiant. Total 2025 revenue was about $5.1 billion.
What usually moves INCY
- Jakafi sales and its patent expiry later this decade
- Opzelura growth and drug-pricing deals with insurers and Medicare
- Late-stage trial results (e.g., mutCALR antibody, povorcitinib, KRAS G12D inhibitor)
- FDA approvals and new product launches
- Business development deals and acquisitions